Sam Brusco, Associate Editor06.25.24
Medical imaging viewer solutions firm Radical Imaging has earned U.S. Food and Drug Administration (FDA) clearance for FlexView Diagnostic, an SaaS (software-as-a-service) web DICOM viewer product.
The viewer for clinicians and radiologists can be used for diagnostic imaging work from anywhere without having to install software, according to the company. The company also said FlexView is straightforward enough for clinical subspecialty imaging users that they don’t need training to use it.
It loads images quickly from the cloud and can support large imaging studies. 3D rendering, multi-modality fusion, and segmentation imaging features are included, and the company said integrating FlexView Diagnostic into a platform takes only a day.
The product enables downloading, reviewing, manipulating, and visualizing medical multi-modality image data in DICOM format and other data. However, it’s not meant for primary diagnosis of mammographic images or diagnostic use on mobile devices, the company advised.
“It is gratifying to see that the OHIF open-source viewer, the result of our ongoing development collaboration with MGH Department of Radiology, is so widely recognized as useful to the medical imaging community,” said Radical Imaging’s CEO Rob Lewis. “Now, with FlexView Diagnostic, we are excited to be able to offer the same excellent user experience to imaging users who require an FDA cleared class II medical device for their diagnostic work. With our secure, scalable, cloud-native, easy to integrate viewer, rigorous quality process, and expert technical support, we aim to simplify and perfect the diagnostic image viewing experience.”
The viewer for clinicians and radiologists can be used for diagnostic imaging work from anywhere without having to install software, according to the company. The company also said FlexView is straightforward enough for clinical subspecialty imaging users that they don’t need training to use it.
It loads images quickly from the cloud and can support large imaging studies. 3D rendering, multi-modality fusion, and segmentation imaging features are included, and the company said integrating FlexView Diagnostic into a platform takes only a day.
The product enables downloading, reviewing, manipulating, and visualizing medical multi-modality image data in DICOM format and other data. However, it’s not meant for primary diagnosis of mammographic images or diagnostic use on mobile devices, the company advised.
“It is gratifying to see that the OHIF open-source viewer, the result of our ongoing development collaboration with MGH Department of Radiology, is so widely recognized as useful to the medical imaging community,” said Radical Imaging’s CEO Rob Lewis. “Now, with FlexView Diagnostic, we are excited to be able to offer the same excellent user experience to imaging users who require an FDA cleared class II medical device for their diagnostic work. With our secure, scalable, cloud-native, easy to integrate viewer, rigorous quality process, and expert technical support, we aim to simplify and perfect the diagnostic image viewing experience.”